Cantargia AB ( (SE:CANTA) ) has issued an announcement.
Cantargia AB has published preclinical data in Cancer Discovery, demonstrating that targeting IL1RAP can effectively inhibit tumor-induced systemic immune suppression, potentially enhancing cancer treatment. The findings, supported by clinical data, show that nadunolimab can reduce immunosuppressive cells and improve the efficacy of cancer vaccines, suggesting significant potential for improving immunotherapy outcomes in cancer treatment.
More about Cantargia AB
Cantargia AB is a biotechnology company that develops antibody-based treatments for life-threatening diseases, focusing on the protein IL1RAP, which is involved in various cancer forms and inflammatory diseases. Their oncology program, featuring the antibody nadunolimab (CAN04), is primarily studied in combination with chemotherapy for pancreatic cancer, non-small cell lung cancer, and triple-negative breast cancer. Cantargia is listed on Nasdaq Stockholm.
YTD Price Performance: -2.61%
Average Trading Volume: 2,500
Technical Sentiment Signal: Buy
Current Market Cap: €36.77M
For detailed information about CANTA stock, go to TipRanks’ Stock Analysis page.